The United States government is currently piloting an ambitious program that leverages artificial intelligence (AI) to make critical insurance-coverage decisions, sparking both hope for efficiency and significant concerns over patient access to care. This initiative, part of a broader effort to reduce healthcare spending, places AI at the forefront of a system that has long been a source of frustration for patients and healthcare providers alike. The core question remains whether this technological leap will streamline a notoriously complex process or inadvertently deepen its existing flaws, potentially leading to increased wrongful denials and delayed, even detrimental, patient outcomes.
The Entrenched Challenges of Prior Authorization
For many Americans, the concept of prior authorization is synonymous with bureaucratic hurdles and exasperating delays. Whether it’s securing approval for a vital prescription, a life-saving medical procedure, or a necessary diagnostic test, the journey through an insurer’s pre-approval process is often fraught with complications. Personal narratives widely document the tribulations of patients navigating these administrative labyrinths, with numerous accounts detailing how individuals are forced to jump through extensive hoops to secure coverage for physician-recommended medical care.
Originally conceived as a crucial mechanism to check healthcare overuse and rein in spending by ensuring services are medically necessary and cost-effective, prior authorization has evolved into a significant bottleneck. It aims to prevent unnecessary procedures or the use of expensive treatments when more affordable, equally effective alternatives exist. However, the practical application of this system often falls short of its theoretical benefits. A substantial majority of physicians, for instance, consistently voice profound concerns about the care delays it imposes. These delays can have severe consequences, including patients abandoning recommended treatments entirely while awaiting insurer verification of eligibility and medical necessity. Such interruptions in care can lead to worsening health conditions and increased suffering.
When a patient is denied care through this process, the recourse is often an appeal—an additional layer of bureaucracy that demands more time and effort, further prolonging access to essential medical services. The administrative burden on healthcare providers is immense, with staff often dedicating countless hours to processing, tracking, and appealing prior authorization requests, diverting resources from direct patient care.
The Promise and Peril of AI in Healthcare Decisions
Against this backdrop of systemic inefficiency, artificial intelligence emerges as a potential game-changer. Proponents argue that AI’s unparalleled ability to rapidly sort and analyze vast quantities of information could theoretically expedite the approval of unambiguously allowable claims. By automating routine decisions, AI could significantly reduce the administrative workload and, critically, shorten care delays for patients. The vision is one where AI acts as a sophisticated digital assistant, quickly sifting through clinical guidelines, patient records, and policy specifics to render swift, accurate decisions.
However, the integration of AI into prior authorization is not without its critics and significant challenges. Early implementations and projections suggest that AI-driven prior authorization could, paradoxically, increase the incidence of wrongful denials of health insurance coverage. A stark illustration of this concern comes from a 2025 American Medical Association (AMA) survey of physicians, which revealed that a significant 61 percent of doctors worry that AI tools will exacerbate denials for treatments they deem medically necessary. This apprehension stems from fears that algorithms might lack the nuanced understanding of individual patient cases that human clinicians possess, leading to blanket denials based on rigid, data-driven parameters.
Health policy analysts like Camm Epstein articulate this concern succinctly, stating that "AI should be used to make appropriate care easier to approve, not necessary care easier to deny." This sentiment underscores a fundamental tension: Is AI being deployed to facilitate care or primarily to control costs, potentially at the expense of patient well-being?
Government Initiatives and a Conflicting Approach
The federal government has initiated steps to address the pervasive issues surrounding prior authorization, albeit with what appears to be a dual, somewhat conflicting strategy.
In 2024, the Biden administration issued a landmark rule aimed at reforming prior authorization for government-run health plans. This regulation mandated specific timelines for insurers to make prior authorization decisions: 72 hours for urgent requests and seven calendar days for non-urgent requests. These timeline requirements officially went into effect on January 1 of this year for most public-sector health plans, including Medicare Advantage, Medicaid managed care plans, and plans on the Affordable Care Act (ACA) marketplaces. The goal was to reduce delays and streamline the process for both patients and physicians within the public healthcare sector.
Concurrently, the Trump administration, through the Centers for Medicare and Medicaid Services (CMS), has embarked on a separate, more technologically focused initiative. In 2025, CMS launched a demonstration project named WISeR, an acronym for Wasteful and Inappropriate Service Reduction Model. This program, slated to run through December 2031 across six states, explicitly integrates AI and machine learning with human clinical review to identify and reduce waste and fraud within original Medicare. WISeR specifically targets services CMS believes are vulnerable to overuse, fraud, and abuse, such as skin and tissue substitutes, electrical nerve stimulator implants, and knee arthroscopy for knee osteoarthritis.
The introduction of prior authorization into original Medicare through WISeR represents a significant policy shift. Historically, prior authorization has been extensively used in Medicare Advantage plans (the privately run alternative to original Medicare, which now covers roughly 55 percent of eligible seniors and disabled individuals), but rarely in traditional Medicare. This expansion of prior authorization, particularly with an AI component, into original Medicare has raised alarms among patient advocates and some lawmakers.
The WISeR Model: Incentives and Controversy
A key element of the WISeR model that has drawn considerable criticism is its financial structure. Vendors participating in the WISeR model, who are hired to carry out the AI-driven prior authorization reviews, earn a share of what CMS terms "averted expenditures." This means these contractors are financially rewarded for rejecting care requests that are deemed unnecessary or inappropriate. This incentive structure immediately raises a red flag, as it creates a direct financial motivation to deny care, potentially conflicting with the paramount goal of ensuring patient access to medically necessary treatments.
Critics argue that this model exacerbates long-standing concerns about profit-making within the healthcare system, particularly when it hinges on discouraging patients from receiving medically necessary care. Wendell Potter, a prominent health insurance reform advocate and former Cigna executive, has covered the political pushback against WISeR extensively, highlighting the ethical dilemmas posed by such financial incentives. Zena Wolf, a researcher with the Center for Health & Democracy, has further underscored these concerns, citing investigations that suggest WISeR has already led to care delays and denials in the pilot states during its initial months of operation, despite the promise of automation.
The administrative burden on healthcare providers, far from being reduced, may actually increase under WISeR. Providers report additional work dealing with denials, requiring more resources to appeal decisions made by the AI system, often without clear explanations. Several lawmakers have responded by introducing resolutions and amendments aimed at blocking funding for the WISeR model, citing its potential to threaten patient access to essential care.
The Broader Landscape of Denials and Appeals
The problem of insurance coverage denials extends far beyond the nascent AI-driven programs. Data consistently highlight the significant burden prior authorization places on the public. A 2026 Commonwealth Fund survey revealed that approximately one in five American working-age adults with private insurance reported that they or a family member were denied coverage for physician-recommended medical care in 2025. Among those who experienced a prior authorization denial, a staggering 41 percent reported that it delayed their care, and more than a quarter indicated that their health problem worsened as a direct result.
In the Medicare Advantage sector, which processes millions of prior authorization determinations annually, federal government reports from June 2026 exposed concerning patterns. The Office of Inspector General (OIG) of the Department of Health and Human Services (HHS) had previously published a memorandum in 2022, pointing to instances where Medicare Advantage plans denied beneficiaries access to services despite those services apparently meeting coverage rules. While plans often overturn a high percentage of denials upon appeal (for example, Medicare Advantage plans overturned 81 percent of denials in 2024), the initial denial process creates significant obstacles, delays, and distress for patients. The OIG reports specifically documented cases where plans rejected requests for skilled nursing and rehabilitation admissions, erecting what critics view as unnecessary obstacles to medically appropriate post-acute care.
Patients often find themselves in a "prior authorization purgatory," as described by NBC News, where they "run out of time or treatment options" while battling for approval. The process of requesting medical exemptions or appealing plan decisions is frequently complicated and cumbersome, requiring a level of tenacity and understanding that many seriously ill patients or their caregivers may not possess.
Industry Responses and Future Outlook
Faced with increasing pressure from both the government and the public, private insurers have also made commitments to reform prior authorization. Last year, in conjunction with the Trump administration, insurers pledged to further streamline and accelerate these processes. Specific vows included standardizing electronic requests by 2027 and committing to "reduce the volume of medical services subject to prior authorization" by 2026, targeting common procedures like colonoscopies and cataract surgeries.
Recent industry data suggest some movement on these pledges. An industry-based survey indicated that between June 2025 and April 2026, requests for prior authorization declined by 11 percent. However, it remains unclear whether this reduction in requests has translated into a decrease in the denial rate, a critical metric for evaluating genuine improvement in patient access.
In response to a survey conducted last year, all responding health plans affirmed that "AI or algorithms without clinician or practitioner review are not used to deny prior authorization requests that involve medical necessity or clinical considerations." Furthermore, insurers promised greater transparency regarding the clinical reasoning underlying prior authorization decisions. This commitment aims to alleviate concerns about a lack of human oversight in AI-driven decisions, which is a major point of contention for many healthcare professionals.
Despite these assurances and pledges, skepticism remains high. Jared Dashevsky, a physician and founder of Healthcare Huddle, articulated a widespread sentiment: "AI could eliminate barriers, reduce administrative waste, give us more time with patients. But that’s not what’s being built." Instead, he warns of an "arms race to deny faster and appeal faster," where AI merely automates and accelerates a fundamentally "broken system" rather than truly fixing it.
The complex interplay of cost control, technological innovation, patient advocacy, and regulatory oversight continues to shape the future of prior authorization. While AI offers tantalizing prospects for efficiency, its deployment in healthcare decision-making carries significant ethical weight and demands rigorous scrutiny to ensure that technological advancements genuinely serve patient well-being, rather than becoming another barrier to necessary care. The ongoing struggle highlights a critical juncture where policy, technology, and human values must align to redefine the pathways to healthcare access in the digital age.
